Cargando…

Salvage Brachytherapy for Biochemically Recurrent Prostate Cancer following Primary Brachytherapy

Purpose. In this study, we evaluated our experience with salvage brachytherapy after discovery of biochemical recurrence after a prior brachytherapy procedure. Methods and Materials. From 2001 through 2012 twenty-one patients treated by brachytherapy within University of Kentucky or from outside cen...

Descripción completa

Detalles Bibliográficos
Autores principales: Lacy, John M., Wilson, William A., Bole, Raevti, Chen, Li, Meigooni, Ali S., Rowland, Randall G., Clair, William H. St.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4820628/
https://www.ncbi.nlm.nih.gov/pubmed/27092279
http://dx.doi.org/10.1155/2016/9561494
_version_ 1782425441217282048
author Lacy, John M.
Wilson, William A.
Bole, Raevti
Chen, Li
Meigooni, Ali S.
Rowland, Randall G.
Clair, William H. St.
author_facet Lacy, John M.
Wilson, William A.
Bole, Raevti
Chen, Li
Meigooni, Ali S.
Rowland, Randall G.
Clair, William H. St.
author_sort Lacy, John M.
collection PubMed
description Purpose. In this study, we evaluated our experience with salvage brachytherapy after discovery of biochemical recurrence after a prior brachytherapy procedure. Methods and Materials. From 2001 through 2012 twenty-one patients treated by brachytherapy within University of Kentucky or from outside centers developed biochemical failure and had no evidence of metastases. Computed tomography (CT) scans were evaluated; patients who had an underseeded portion of their prostate were considered for reimplantation. Results. The majority of the patients in this study (61.9%) were low risk and median presalvage PSA was 3.49 (range 17.41–1.68). Mean follow-up was 61 months. At last follow-up after reseeding, 11/21 (52.4%) were free of biochemical recurrence. There was a trend towards decreased freedom from biochemical recurrence in low risk patients (p = 0.12). International Prostate Symptom Scores (IPSS) increased at 3-month follow-up visits but decreased and were equivalent to baseline scores at 18 months. Conclusions. Salvage brachytherapy after primary brachytherapy is possible; however, in our experience the side-effect profile after the second brachytherapy procedure was higher than after the first brachytherapy procedure. In this cohort of patients we demonstrate that approximately 50% oncologic control, low risk patients appear to have better outcomes than others.
format Online
Article
Text
id pubmed-4820628
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-48206282016-04-18 Salvage Brachytherapy for Biochemically Recurrent Prostate Cancer following Primary Brachytherapy Lacy, John M. Wilson, William A. Bole, Raevti Chen, Li Meigooni, Ali S. Rowland, Randall G. Clair, William H. St. Prostate Cancer Research Article Purpose. In this study, we evaluated our experience with salvage brachytherapy after discovery of biochemical recurrence after a prior brachytherapy procedure. Methods and Materials. From 2001 through 2012 twenty-one patients treated by brachytherapy within University of Kentucky or from outside centers developed biochemical failure and had no evidence of metastases. Computed tomography (CT) scans were evaluated; patients who had an underseeded portion of their prostate were considered for reimplantation. Results. The majority of the patients in this study (61.9%) were low risk and median presalvage PSA was 3.49 (range 17.41–1.68). Mean follow-up was 61 months. At last follow-up after reseeding, 11/21 (52.4%) were free of biochemical recurrence. There was a trend towards decreased freedom from biochemical recurrence in low risk patients (p = 0.12). International Prostate Symptom Scores (IPSS) increased at 3-month follow-up visits but decreased and were equivalent to baseline scores at 18 months. Conclusions. Salvage brachytherapy after primary brachytherapy is possible; however, in our experience the side-effect profile after the second brachytherapy procedure was higher than after the first brachytherapy procedure. In this cohort of patients we demonstrate that approximately 50% oncologic control, low risk patients appear to have better outcomes than others. Hindawi Publishing Corporation 2016 2016-03-22 /pmc/articles/PMC4820628/ /pubmed/27092279 http://dx.doi.org/10.1155/2016/9561494 Text en Copyright © 2016 John M. Lacy et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Lacy, John M.
Wilson, William A.
Bole, Raevti
Chen, Li
Meigooni, Ali S.
Rowland, Randall G.
Clair, William H. St.
Salvage Brachytherapy for Biochemically Recurrent Prostate Cancer following Primary Brachytherapy
title Salvage Brachytherapy for Biochemically Recurrent Prostate Cancer following Primary Brachytherapy
title_full Salvage Brachytherapy for Biochemically Recurrent Prostate Cancer following Primary Brachytherapy
title_fullStr Salvage Brachytherapy for Biochemically Recurrent Prostate Cancer following Primary Brachytherapy
title_full_unstemmed Salvage Brachytherapy for Biochemically Recurrent Prostate Cancer following Primary Brachytherapy
title_short Salvage Brachytherapy for Biochemically Recurrent Prostate Cancer following Primary Brachytherapy
title_sort salvage brachytherapy for biochemically recurrent prostate cancer following primary brachytherapy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4820628/
https://www.ncbi.nlm.nih.gov/pubmed/27092279
http://dx.doi.org/10.1155/2016/9561494
work_keys_str_mv AT lacyjohnm salvagebrachytherapyforbiochemicallyrecurrentprostatecancerfollowingprimarybrachytherapy
AT wilsonwilliama salvagebrachytherapyforbiochemicallyrecurrentprostatecancerfollowingprimarybrachytherapy
AT boleraevti salvagebrachytherapyforbiochemicallyrecurrentprostatecancerfollowingprimarybrachytherapy
AT chenli salvagebrachytherapyforbiochemicallyrecurrentprostatecancerfollowingprimarybrachytherapy
AT meigoonialis salvagebrachytherapyforbiochemicallyrecurrentprostatecancerfollowingprimarybrachytherapy
AT rowlandrandallg salvagebrachytherapyforbiochemicallyrecurrentprostatecancerfollowingprimarybrachytherapy
AT clairwilliamhst salvagebrachytherapyforbiochemicallyrecurrentprostatecancerfollowingprimarybrachytherapy